^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Solid tumor CAR-T therapy

    i
    Other names: Solid tumor CAR-T therapy
    Associations

    News

    Trials
    Company:
    Anixa Biosci, Moffitt Cancer Center
    Drug class:
    FSHR-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    over3years
    An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity (SITC 2022)
    6 Tempus xT-Onco reliably detects HLA LOH and quantifies CEA and MSLN expression. Based on these data, patients with solid tumors are now being prospectively screened for HLA LOH using xT-Onco in an ongoing tissue banking study (BASECAMP-1, NCT04981119 ), preparing for future interventional protocols.
    Clinical • Tumor mutational burden • IO biomarker • Next-generation sequencing
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    MSLN expression • CEACAM5 expression • HLA-A*02 • CEACAM5 overexpression
    |
    Tempus xT Assay
    |
    Solid tumor CAR-T therapy